BRPI0416172A - polìmero ligante a ánion, composição farmacêutica, polìmeros ligantes a fosfato e a ìons, e, métodos para medir a interferência à ligação ao ìon alvo para um polìmero ligante a ìon, de seleção de um polìmero ligante a ìons que se ligam a um ìon alvo, para melhoria das propriedades terapêuticas e/ou adequação para administração e/ou propriedades farmacêuticas de um polìmero poliamìnico, de fabricar um polìmero ligante a ìons que se liga a um ánion alvo, e de remoção de um ánion de um animal - Google Patents

polìmero ligante a ánion, composição farmacêutica, polìmeros ligantes a fosfato e a ìons, e, métodos para medir a interferência à ligação ao ìon alvo para um polìmero ligante a ìon, de seleção de um polìmero ligante a ìons que se ligam a um ìon alvo, para melhoria das propriedades terapêuticas e/ou adequação para administração e/ou propriedades farmacêuticas de um polìmero poliamìnico, de fabricar um polìmero ligante a ìons que se liga a um ánion alvo, e de remoção de um ánion de um animal

Info

Publication number
BRPI0416172A
BRPI0416172A BRPI0416172-6A BRPI0416172A BRPI0416172A BR PI0416172 A BRPI0416172 A BR PI0416172A BR PI0416172 A BRPI0416172 A BR PI0416172A BR PI0416172 A BRPI0416172 A BR PI0416172A
Authority
BR
Brazil
Prior art keywords
ion
anion
binding
polymer
binding polymer
Prior art date
Application number
BRPI0416172-6A
Other languages
English (en)
Inventor
Eric Connor
Dominique Charmot
Han Ting Chang
Florence Roger
Gerrit Klearner
Son Hoal Nguyen
Original Assignee
Ilypsa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/701,385 external-priority patent/US7385012B2/en
Priority claimed from US10/806,495 external-priority patent/US7335795B2/en
Application filed by Ilypsa Inc filed Critical Ilypsa Inc
Publication of BRPI0416172A publication Critical patent/BRPI0416172A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F26/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F26/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F26/06—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a heterocyclic ring containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/0206—Polyalkylene(poly)amines
    • C08G73/0213—Preparatory process
    • C08G73/022—Preparatory process from polyamines and epihalohydrins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L39/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions of derivatives of such polymers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L39/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions of derivatives of such polymers
    • C08L39/02—Homopolymers or copolymers of vinylamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

"POLìMERO LIGANTE A áNION, COMPOSIçãO FARMACêUTICA, POLìMEROS LIGANTES A FOSFATO E A ìONS, E, MéTODOS PARA MEDIR A INTERFERêNCIA à LIGAçãO AO ìON ALVO PARA UM POLìMERO LIGANTE A ìON, DE SELEçãO DE UM POLìMERO LIGANTE A ìONS QUE SE LIGAM A UM ìON ALVO, PARA MELHORIA DAS PROPRIEDADES TERAPêUTICAS E/OU ADEQUAçãO PARA ADMINISTRAçãO E/OU PROPRIEDADES FARMACêUTICAS DE UM POLìMERO POLIAMìNICO, DE FABRICAR UM POLìMERO LIGANTE A ìONS QUE SE LIGA A UM áNION ALVO, E DE REMOçãO DE UM áNION DE UM ANIMAL". Descrição de polímeros de ligantes (quelantes) de ânions. Em alguns casos, os polímeros ligantes a ânions são polímeros de baixo intumescimento. Em alguns casos, esses polímeros de ligação a ânions têm uma distribuição do volume de poros tal que uma fração do polímero não está disponível para solutos não interagentes maiores do que um dado percentual do peso molecular do íon alvo do polímero. Os polímeros ligantes a ânions são caracterizados pela baixa interferência na ligação de ânions quando essa interferência é medida, por exemplo, por meio de um pseudo-agente gastrintestinal, quando comparado com a mesma medida num tampão não interferente. A patente também descreve a composição farmacêutica, a metodologia de uso e kits.
BRPI0416172-6A 2003-11-03 2004-11-03 polìmero ligante a ánion, composição farmacêutica, polìmeros ligantes a fosfato e a ìons, e, métodos para medir a interferência à ligação ao ìon alvo para um polìmero ligante a ìon, de seleção de um polìmero ligante a ìons que se ligam a um ìon alvo, para melhoria das propriedades terapêuticas e/ou adequação para administração e/ou propriedades farmacêuticas de um polìmero poliamìnico, de fabricar um polìmero ligante a ìons que se liga a um ánion alvo, e de remoção de um ánion de um animal BRPI0416172A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/701,385 US7385012B2 (en) 2003-11-03 2003-11-03 Polyamine polymers
US10/806,495 US7335795B2 (en) 2004-03-22 2004-03-22 Crosslinked amine polymers
US10/965,044 US7459502B2 (en) 2003-11-03 2004-10-13 Pharmaceutical compositions comprising crosslinked polyamine polymers
PCT/US2004/036745 WO2005041902A2 (en) 2003-11-03 2004-11-03 Anion-binding polymers and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0416172A true BRPI0416172A (pt) 2007-01-16

Family

ID=34557428

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416172-6A BRPI0416172A (pt) 2003-11-03 2004-11-03 polìmero ligante a ánion, composição farmacêutica, polìmeros ligantes a fosfato e a ìons, e, métodos para medir a interferência à ligação ao ìon alvo para um polìmero ligante a ìon, de seleção de um polìmero ligante a ìons que se ligam a um ìon alvo, para melhoria das propriedades terapêuticas e/ou adequação para administração e/ou propriedades farmacêuticas de um polìmero poliamìnico, de fabricar um polìmero ligante a ìons que se liga a um ánion alvo, e de remoção de um ánion de um animal

Country Status (17)

Country Link
US (1) US7459502B2 (pt)
EP (5) EP2009042B1 (pt)
JP (3) JP3996944B2 (pt)
KR (1) KR101052581B1 (pt)
AT (5) ATE364057T1 (pt)
AU (1) AU2004285609B2 (pt)
BR (1) BRPI0416172A (pt)
CA (1) CA2542730C (pt)
CY (3) CY1107728T1 (pt)
DE (5) DE112004002099T5 (pt)
DK (3) DK1682606T3 (pt)
ES (4) ES2330693T3 (pt)
GB (1) GB2426248B (pt)
PL (3) PL1682606T3 (pt)
PT (3) PT1682606E (pt)
SI (3) SI1854826T1 (pt)
WO (2) WO2005041900A2 (pt)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
US20060083791A1 (en) 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US7381428B2 (en) * 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
EP1660104B1 (en) * 2003-08-26 2010-03-10 Shire Holdings AG Pharmaceutical formulation comprising lanthanum compounds
US7385012B2 (en) 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7608674B2 (en) * 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7767768B2 (en) * 2003-11-03 2010-08-03 Ilypsa, Inc. Crosslinked amine polymers
US7335795B2 (en) 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7449605B2 (en) * 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
JP2008516971A (ja) * 2004-10-15 2008-05-22 アルテアーナノ，インコーポレーテッド 錠剤による負荷が軽減されるリン酸塩結合剤
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
US20060177415A1 (en) * 2004-11-01 2006-08-10 Burke Steven K Once a day formulation for phosphate binders
ITME20040015A1 (it) 2004-12-07 2005-03-07 Vincenzo Savica Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico.
AU2006279343A1 (en) * 2005-08-17 2007-02-22 Altairnano, Inc. Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods
JP2009504781A (ja) * 2005-08-17 2009-02-05 アルテアナノ インコーポレイテッド 家畜における高リン血症：治療のための組成物、及び治療方法
US8986669B2 (en) 2005-09-02 2015-03-24 Genzyme Corporation Method for removing phosphate and polymer used therefore
US8114393B2 (en) * 2005-09-14 2012-02-14 Wisconsin Alumni Research Foundation Methods and compositions for phosphate binding
US8158117B2 (en) 2005-09-14 2012-04-17 Wisconsin Alumni Research Foundation Methods and compositions for phosphate binding
AU2012205214B2 (en) * 2005-09-15 2015-05-21 Genzyme Corporation Formulation for Amine Polymers
HUE026628T2 (en) * 2005-09-15 2016-06-28 Genzyme Corp Pouches for amine polymers
WO2007041569A1 (en) * 2005-09-30 2007-04-12 Ilypsa, Inc. Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal
BRPI0616603A2 (pt) * 2005-09-30 2012-12-25 Ilypsa Inc mÉtodo para preparar um compàsito de nécleo-envoltàrio, e para a manufatura de um medicamento, composiÇço farmacÊutica, e, uso da mesma
AU2007203715B2 (en) * 2006-01-05 2012-08-02 Veloxis Pharmaceuticals A/S Disintegrating loadable tablets
US20070177866A1 (en) * 2006-01-31 2007-08-02 Yoshizo Fujimoto Camera extension arm
CN101404982A (zh) * 2006-02-14 2009-04-08 特瓦制药工业有限公司 脂族胺聚合物的药物制剂和它们的制造方法
CN100398112C (zh) * 2006-03-24 2008-07-02 辽宁诺康生物制药有限责任公司 一种治疗血磷酸盐过多症的药物及其制备方法
EP2016114A2 (en) * 2006-05-05 2009-01-21 Genzyme Corporation Amine condensation polymers as phosphate sequestrants
US20100124542A1 (en) * 2006-07-18 2010-05-20 Genzyme Corporation Amine dendrimers
CA2749074A1 (en) * 2006-09-01 2008-05-29 Usv Limited Process for the preparation of sevelamer hydrochloride and formulation thereof
US7964182B2 (en) * 2006-09-01 2011-06-21 USV, Ltd Pharmaceutical compositions comprising phosphate-binding polymer
EP2066293A2 (en) 2006-09-29 2009-06-10 Genzyme Corporation Amide dendrimer compositions
US8163799B2 (en) 2006-12-14 2012-04-24 Genzyme Corporation Amido-amine polymer compositions
JP2010519298A (ja) * 2007-02-23 2010-06-03 ゲンズイメ コーポレーション アミンポリマー組成物
JP2010520285A (ja) * 2007-03-08 2010-06-10 ゲンズイメ コーポレーション スルホンポリマー組成物
US20100166696A1 (en) * 2007-04-27 2010-07-01 Dhal Pradeep K Amido-amine dendrimer compositions
KR20100045965A (ko) * 2007-07-11 2010-05-04 도레이 카부시키가이샤 가교 폴리알릴아민 또는 그 산부가염 및 그 의약 용도
EP2016947A1 (en) * 2007-07-17 2009-01-21 Chemo Ibérica, S.A. Novel one step process for preparing cross-linked poly(allylamine) polymers
WO2009023544A2 (en) * 2007-08-10 2009-02-19 Ilypsa, Inc. Dosage unit anion-exchange polymer pharmaceutical compositions
WO2009034540A1 (en) * 2007-09-11 2009-03-19 Ranbaxy Laboratories Limited Pharmaceutical composition of sevelamer
JP5332520B2 (ja) * 2007-11-07 2013-11-06 アステラス製薬株式会社 医薬用錠剤
WO2009097127A1 (en) * 2008-01-31 2009-08-06 Genzyme Corporation Pharmaceutical compositions
WO2009154747A1 (en) * 2008-06-20 2009-12-23 Genzyme Corporation Pharmaceutical compositions
EP2389168A2 (en) * 2009-01-22 2011-11-30 USV Limited Pharmaceutical compositions comprising phosphate-binding polymer
IT1394299B1 (it) * 2009-05-12 2012-06-06 Chimico Internaz Spa Lab Procedimento per la preparazione di sevelamer
WO2011106548A1 (en) * 2010-02-24 2011-09-01 Relypsa, Inc. Amine polymers for use as bile acid sequestrants
CN102858347B (zh) * 2010-02-24 2016-11-02 瑞立普萨公司 用作胆汁酸螯合剂的聚咪唑
CN105017481B (zh) 2010-02-24 2018-10-02 瑞立普萨公司 用作胆汁酸螯合剂的交联聚乙烯胺、聚烯丙胺和乙烯亚胺
ES2871021T3 (es) 2010-05-12 2021-10-28 Spectrum Pharmaceuticals Inc Hidróxido de carbonato de lantano, oxicarbonato de lantano y procedimientos de fabricación y uso
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US10369529B2 (en) 2012-01-30 2019-08-06 California Institute Of Technology Mixed matrix membranes with embedded polymeric particles and networks and related compositions, methods, and systems
EP2557074A1 (en) 2011-08-11 2013-02-13 Astellas Pharma Inc. Process for the preparation of N,N,N',N'-tetrakis(3-aminopropyl)-1,4-butanediamine
WO2013116408A1 (en) 2012-01-30 2013-08-08 California Institute Of Technology Filtration membranes and related compositions, methods and systems
ES3037037T3 (en) 2012-07-19 2025-09-26 Ecolab Usa Inc High efficiency wet strength resins from new cross-linkers
HK1220607A1 (zh) * 2013-03-15 2017-05-12 Genzyme Corporation 晚期糖化终产物(age)前体的螯合剂
EP3003327B1 (en) * 2013-06-05 2017-08-09 Tricida Inc. Proton-binding polymers for oral administration
US10435528B2 (en) 2013-09-17 2019-10-08 Aquanano Llc High-capacity anion exchange materials
JP5843986B2 (ja) * 2014-03-25 2016-01-13 アステラス製薬株式会社 粒状医薬組成物
WO2016043808A1 (en) 2014-09-17 2016-03-24 Aquanano Llc High-capacity anion exchange material
RS61409B1 (sr) * 2014-12-10 2021-03-31 Tricida Inc Polimeri koji vezuju protone za oralnu primenu opis
WO2016164315A1 (en) * 2015-04-06 2016-10-13 3M Innovative Properties Company Removable film forming gel compositions and methods for their application
CA2987852C (en) * 2015-05-29 2023-03-14 Georgia-Pacific Chemicals Llc High efficiency wet strength resins from new cross-linkers
CN109414453B (zh) 2016-05-06 2023-02-17 特里赛达公司 用于治疗酸碱失衡的组合物
EP3564292B1 (en) 2016-12-28 2021-06-16 FUJIFILM Corporation Emulsion of nitrogen atom-containing polymer or salt thereof, production method therefor, and production method for particles
CN107141408A (zh) * 2017-06-12 2017-09-08 厦门建霖健康家居股份有限公司 一种抗菌聚合物及其制备方法
US10934380B1 (en) 2017-09-25 2021-03-02 Tricida, Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions
JP7018451B2 (ja) 2017-10-16 2022-02-10 富士フイルム株式会社 高リン血症治療剤および粒子
CN111225674A (zh) 2017-10-16 2020-06-02 富士胶片株式会社 高磷血症治疗剂
CA3080651A1 (en) 2017-11-03 2019-05-09 Tricida, Inc. Compositions for and method of treating acid-base disorders
JP2021093979A (ja) * 2019-12-18 2021-06-24 太陽化学株式会社 難水溶性物質含有組成物
CN111521705B (zh) * 2020-05-05 2021-04-20 大连润生康泰医学检验实验室有限公司 一种血清中胆汁酸的富集方法
WO2023064357A1 (en) * 2021-10-13 2023-04-20 Tricida, Inc. Pharmaceutical compositions for the treatment of lithiasis disorders
CN115260355A (zh) * 2022-05-16 2022-11-01 江苏中天药业有限公司 一种阴离子交换树脂、其制备方法、该树脂与药物的复合物和其掩味制剂

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US814789A (en) 1904-12-21 1906-03-13 Edward D Mackintosh Drawing and plotting device.
US3308020A (en) 1961-09-22 1967-03-07 Merck & Co Inc Compositions and method for binding bile acids in vivo including hypocholesteremics
US3499960A (en) 1965-01-25 1970-03-10 Merck & Co Inc Palatable coated particles of an anion exchange resin
US3692895A (en) 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
US3974272A (en) 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US4027009A (en) 1973-06-11 1977-05-31 Merck & Co., Inc. Compositions and methods for depressing blood serum cholesterol
US3930810A (en) 1974-07-31 1976-01-06 Universal Oil Products Company Additives for petroleum distillates
US4015939A (en) 1976-05-12 1977-04-05 Bio-Rad Laboratories, Inc. Competitive binding thyroid assay with improved bound-free separation step
US4135880A (en) 1977-08-19 1979-01-23 Bio-Rad Laboratories, Inc. Folate assay with ion exchange resin bound-free separation
US4362711A (en) 1980-07-11 1982-12-07 Evreka Inc. Blood cholesterol level reducing agent and method
US4410688A (en) 1981-04-29 1983-10-18 Allied Corporation Macromolecular highly branched homogeneous compound
US4558120A (en) 1983-01-07 1985-12-10 The Dow Chemical Company Dense star polymer
US4568737A (en) 1983-01-07 1986-02-04 The Dow Chemical Company Dense star polymers and dendrimers
US4507466A (en) 1983-01-07 1985-03-26 The Dow Chemical Corporation Dense star polymers having core, core branches, terminal groups
US4631337A (en) 1983-01-07 1986-12-23 The Dow Chemical Company Hydrolytically-stable dense star polyamine
US4737550A (en) 1983-01-07 1988-04-12 The Dow Chemical Company Bridged dense star polymers
JPS6090243A (ja) 1983-10-25 1985-05-21 Nitto Boseki Co Ltd 小球状モノアリルアミン橋かけ重合体の製造方法
US4587329A (en) 1984-08-17 1986-05-06 The Dow Chemical Company Dense star polymers having two dimensional molecular diameter
US4599400A (en) 1984-12-18 1986-07-08 The Dow Chemical Company Star/comb-branched polyamide
US4747881A (en) 1985-02-05 1988-05-31 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US4734200A (en) 1986-04-04 1988-03-29 Advanced Separation Technologies Incorporated Process for removal of fluoride and phosphorus-type contaminants from acidic wastewater
IT1190349B (it) 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
US5338532A (en) 1986-08-18 1994-08-16 The Dow Chemical Company Starburst conjugates
US5807582A (en) 1988-08-26 1998-09-15 Pharmacia & Upjohn Company Fine-beaded colestipol hydrochloride and pharmaceutically elegant dosage forms made therefrom
GB8829088D0 (en) 1988-12-13 1989-01-25 Smith Kline French Lab Compounds
US5091175A (en) 1990-05-14 1992-02-25 Erbamont Inc. Pharmaceutical composition containing bile acid sequestrant enclosed in a size-exclusion membrane
FR2680791B1 (fr) 1991-08-30 1994-09-09 Bp Chemicals Snc Procede de fabrication d'un polymere reticule et utilisation du polymere.
US5530092A (en) 1992-01-13 1996-06-25 Dsm N.V. Dendritic macromolecule and the preparation thereof
BE1007260A3 (nl) 1993-07-08 1995-05-02 Dsm Nv Werkwijze voor het bereiden van een dendritisch macromolekuul.
JPH06506501A (ja) 1992-01-13 1994-07-21 デーエスエム ナムローゼ フェンノートシャップ デンドライト高分子およびその製造
US5380522A (en) 1992-08-11 1995-01-10 Day; Charles E. Method for treatment of irritable bowel syndrome
US5556619A (en) 1992-08-20 1996-09-17 The Du Pont Merck Pharmaceutical Company Crosslinked polymeric ammonium salts
US5451397A (en) * 1992-12-21 1995-09-19 Rohm And Haas Company Bile acid sequestrant
DK0684958T3 (da) 1993-02-17 1998-10-19 Btg Int Ltd Polymerer indeholdende guanidinogrupper til anvendelse i terapi
AU6818894A (en) 1993-05-20 1994-12-20 Geltex Pharmaceuticals, Inc. Process for adjusting ion concentration in a patient and compositions therefor
US5487888A (en) 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US6129910A (en) 1993-06-02 2000-10-10 Geltex Pharmaceuticals, Inc. Water-insoluble noncrosslinked bile acid sequestrants
US5607669A (en) 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5618530A (en) 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
CA2129079C (en) 1993-08-03 2006-01-17 Tatsuo Nomura Orally administrable cholesterol lowering agent
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5496545A (en) * 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5414068A (en) 1994-01-24 1995-05-09 Rohm And Haas Company Crosslinked anion exchange particles and method for producing the particles
JPH09508170A (ja) 1994-01-28 1997-08-19 デーエスエム ナムローゼ フェンノートシャップ 樹枝状高分子物質およびその製造法
BE1008134A3 (nl) 1994-03-16 1996-01-23 Dsm Nv Bereiding van stervormig vertakte polymeren.
TW474813B (en) 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
GB9503061D0 (en) 1995-02-16 1995-04-05 British Tech Group Polymeric compounds
US6060604A (en) 1995-03-31 2000-05-09 Florida State University Pharmaceutical compounds comprising polyamines substituted with electron-affinic groups
NL1001973C2 (nl) 1995-12-21 1997-06-24 Stork Friesland Bv Semipermeabel composietmembraan.
NL1001977C2 (nl) 1995-12-22 1997-06-24 Dsm Nv Werkwijze voor de bereiding van een macromolekuul.
EP0793960B1 (en) 1996-03-05 2001-08-01 Mitsubishi Chemical Corporation Use of anion exchange resins for the manufacture of a medicament for the treatment of hyperphosphatemia
JP3885130B2 (ja) 1996-06-11 2007-02-21 株式会社大塚製薬工場 グアニジノ化合物低下剤並びに水分及びカリウムイオン吸着剤
US6034129A (en) 1996-06-24 2000-03-07 Geltex Pharmaceuticals, Inc. Ionic polymers as anti-infective agents
CA2258744A1 (en) 1996-06-27 1997-12-31 G.D. Searle And Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
CN1230118A (zh) 1996-07-19 1999-09-29 日研化学株式会社 高磷血症治疗剂
NZ335329A (en) 1996-10-23 2001-06-29 Dow Chemical Co Water soluble polyether glycol polymer capable of complexing phosphate or oxalate used for reduction of dietary phosphate or oxalate absorption
JPH10130154A (ja) 1996-10-29 1998-05-19 Otsuka Pharmaceut Factory Inc 腎疾患患者用延命率改善薬
AU2446497A (en) 1997-03-25 1998-10-20 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers combined with a calcium supplement for oral administration
JP2003183168A (ja) * 1997-04-04 2003-07-03 Chugai Pharmaceut Co Ltd リン酸結合性ポリマー含有製剤
TW592727B (en) 1997-04-04 2004-06-21 Chugai Pharmaceutical Co Ltd Phosphate-binding polymer preparations
US6423754B1 (en) 1997-06-18 2002-07-23 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with polyallylamine polymers
CN1210390C (zh) 1997-09-15 2005-07-13 普罗格特-甘布尔公司 含有基于直链胺的聚合物以改善被洗涤织物的外观和完整效果的洗衣洗涤剂组合物
US6007803A (en) 1997-09-19 1999-12-28 Geltex Pharmaceuticals, Inc. Ionic polymers as toxin binding agents
US20040170600A1 (en) 1997-10-22 2004-09-02 Jaime Simon Water-soluble polymers for the reduction of dietary phosphate or oxalate absorption
US5985938A (en) 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6726905B1 (en) 1997-11-05 2004-04-27 Genzyme Corporation Poly (diallylamines)-based phosphate binders
US6566407B2 (en) 1997-11-05 2003-05-20 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
CA2315088A1 (en) 1997-12-19 1999-07-01 Smithkline Beecham Corporation Process for manufacturing bite-dispersion tablets
WO1999040990A1 (en) 1998-02-17 1999-08-19 University Of Maryland Anion binding polymers and the use thereof
US6333051B1 (en) 1998-09-03 2001-12-25 Supratek Pharma, Inc. Nanogel networks and biological agent compositions thereof
TW568788B (en) 1998-10-12 2004-01-01 Chugai Pharmaceutical Co Ltd Polymer combining with phosphoric acid and preparation containing the same
JP3363143B2 (ja) * 1998-10-12 2003-01-08 中外製薬株式会社 リン酸結合性ポリマー粒子
US6361768B1 (en) 1998-12-29 2002-03-26 Pmd Holdings Corp. Hydrophilic ampholytic polymer
US6362266B1 (en) 1999-09-03 2002-03-26 The Dow Chemical Company Process for reducing cohesiveness of polyallylamine polymer gels during drying
US6180754B1 (en) 1999-09-03 2001-01-30 The Dow Chemical Company Process for producing cross-linked polyallylamine polymer
US20020054903A1 (en) 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
ATE286386T1 (de) 1999-10-19 2005-01-15 Genzyme Corp Direktkomprimierter tablettenkern auf polymerbasis
FI109353B (fi) 1999-11-17 2002-07-15 Neste Chemicals Oy Maleimidimodifioidut poly(propyleeni-imiini)dendrimeerit ja menetelmä niiden valmistamiseksi
WO2001066607A1 (en) * 2000-03-09 2001-09-13 Hisamitsu Pharmaceutical Co., Inc. Crosslinked anion-exchange resin or salt thereof and phosphorus adsorbent comprising the same
AU2001241076A1 (en) 2000-03-09 2001-09-17 Hisamitsu Pharmaceutical Co. Inc. Crosslinked anion-exchange resin or salt thereof
DE10011481A1 (de) 2000-03-09 2001-10-18 Fresenius Hemocare Gmbh Adsorbens zum Absenken der Konzentration von Fibrinogen und/oder Fibrin, Verwendung des Adsorbens zur Herstellung eines Adsorbers und Adsorber mit dem Adsorbens
US20030091530A1 (en) 2000-03-13 2003-05-15 Takeshi Goto Preventives and/or remedies for hyperphosphatemia
US6471968B1 (en) 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
GB2374072B (en) 2000-06-16 2004-09-22 Nippon Catalytic Chem Ind Crosslinked polymer method for manufacturing it and use thereof
WO2002032974A2 (en) 2000-10-18 2002-04-25 Fujisawa Pharmaceutical Co., Ltd. Polymer and its use for the treatment and/or prevention of hyperphosphoremia
DE10056840A1 (de) 2000-11-16 2002-05-23 Basf Ag Verfahren zur Hydrierung von Nitrilen an Raney-Katalysatoren
AU2002232955A1 (en) 2000-11-20 2002-05-27 Dow Global Technologies Inc. In vivo use of water absorbent polymers
WO2002066543A1 (en) 2001-02-16 2002-08-29 Genzyme Corporation Method of drying a material having a cohesive phase
EP1373368B1 (en) 2001-03-27 2013-02-27 Firmenich SA Compounds for a controlled release of active compounds
WO2002085383A1 (en) 2001-04-18 2002-10-31 Genzyme Corporation Method for reducing copper levels and treating copper toxicosis
WO2002085380A1 (en) 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for treating gout and reducing serum uric acid
WO2002085379A1 (en) 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for improving vascular access in patients with vascular shunts
AU2002257145B2 (en) 2001-04-18 2005-06-02 Genzyme Corporation Method for lowering serum glucose
CA2444028A1 (en) 2001-04-18 2002-10-31 Genzyme Corporation Methods of treating syndrome x with aliphatic polyamines
WO2002085381A1 (en) 2001-04-18 2002-10-31 Genzyme Corporation Method for treating gout and binding uric acid
US6600011B2 (en) 2001-10-09 2003-07-29 Genzyme Corporation Process for purification and drying of polymer hydrogels
JP3931639B2 (ja) 2001-11-19 2007-06-20 セイコーエプソン株式会社 インクジェットプリンタに使用するための水性インク組成物
WO2004037274A1 (en) 2002-10-22 2004-05-06 Genzyme Corporation Amine polymers for promoting bone formation
DE10305807A1 (de) 2003-02-12 2004-08-26 Basf Ag Polymethylenamine und Verfahren zu deren Herstellung
US7385012B2 (en) 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7335795B2 (en) 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7449605B2 (en) 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7608674B2 (en) 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
CA2551528A1 (en) 2003-12-31 2005-07-21 Genzyme Corporation Enteric coated aliphatic amine polymer bile acid sequestrants
US20050276781A1 (en) 2004-06-09 2005-12-15 Ross Edward A Molecularly imprinted phosphate binders for therapeutic use
JP2008531751A (ja) 2004-10-13 2008-08-14 イリプサ， インコーポレイテッド 架橋アミンポリマー
GB0422877D0 (en) 2004-10-14 2004-11-17 Univ Glasgow Bioactive polymers

Also Published As

Publication number Publication date
KR20070026338A (ko) 2007-03-08
EP1834976A1 (en) 2007-09-19
ATE445662T1 (de) 2009-10-15
CY1110562T1 (el) 2015-04-29
GB0610607D0 (en) 2006-07-05
HK1101697A1 (zh) 2007-10-26
EP1687349A2 (en) 2006-08-09
ATE546482T1 (de) 2012-03-15
DK1854826T3 (da) 2009-01-12
US20050131138A1 (en) 2005-06-16
EP2009042A1 (en) 2008-12-31
EP2009042B1 (en) 2009-10-14
GB2426248B (en) 2008-08-13
DE602004006892D1 (de) 2007-07-19
JP2007510783A (ja) 2007-04-26
PL1854826T3 (pl) 2009-06-30
CY1110475T1 (el) 2015-04-29
WO2005041902A2 (en) 2005-05-12
ES2318823T3 (es) 2009-05-01
PT1854826E (pt) 2008-12-15
ES2330693T3 (es) 2009-12-14
DK1682606T3 (da) 2007-10-01
WO2005041900A2 (en) 2005-05-12
EP1682606B1 (en) 2007-06-06
DK2009042T3 (da) 2009-11-30
EP1682606A4 (en) 2006-12-20
DE602004006892T2 (de) 2008-02-07
WO2005041900A3 (en) 2006-06-08
PT2009042E (pt) 2009-10-23
JP2007262421A (ja) 2007-10-11
EP1854826A1 (en) 2007-11-14
KR101052581B1 (ko) 2011-07-29
DE602004023661D1 (de) 2009-11-26
ATE414730T1 (de) 2008-12-15
CA2542730C (en) 2012-07-10
ATE364057T1 (de) 2007-06-15
CY1107728T1 (el) 2013-04-18
WO2005041902A3 (en) 2006-05-18
JP4902864B2 (ja) 2012-03-21
EP1682606A2 (en) 2006-07-26
US7459502B2 (en) 2008-12-02
JP2007146180A (ja) 2007-06-14
EP1687349A4 (en) 2006-12-27
PL2009042T3 (pl) 2010-05-31
AU2004285609B2 (en) 2009-04-23
EP1854826B1 (en) 2008-11-19
PT1682606E (pt) 2007-09-05
EP1687349B1 (en) 2008-06-18
SI2009042T1 (sl) 2009-12-31
PL1682606T3 (pl) 2007-10-31
DE602004017918D1 (de) 2009-01-02
ATE398636T1 (de) 2008-07-15
EP1834976B1 (en) 2012-02-22
JP5074838B2 (ja) 2012-11-14
ES2308294T3 (es) 2008-12-01
JP3996944B2 (ja) 2007-10-24
ES2287806T3 (es) 2007-12-16
GB2426248A (en) 2006-11-22
DE602004014527D1 (de) 2008-07-31
DE112004002099T5 (de) 2007-01-04
SI1682606T1 (sl) 2007-10-31
SI1854826T1 (sl) 2009-06-30
AU2004285609A1 (en) 2005-05-12
CA2542730A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
BRPI0416172A (pt) polìmero ligante a ánion, composição farmacêutica, polìmeros ligantes a fosfato e a ìons, e, métodos para medir a interferência à ligação ao ìon alvo para um polìmero ligante a ìon, de seleção de um polìmero ligante a ìons que se ligam a um ìon alvo, para melhoria das propriedades terapêuticas e/ou adequação para administração e/ou propriedades farmacêuticas de um polìmero poliamìnico, de fabricar um polìmero ligante a ìons que se liga a um ánion alvo, e de remoção de um ánion de um animal
De Vos et al. Imidazoline receptors, non-adrenergic idazoxan binding sites and α2-adrenoceptors in the human central nervous system
Zanoni et al. Irradiation causes senescence, ATP release, and P2X7 receptor isoform switch in glioblastoma
Corby et al. Decreased alpha-adrenergic receptors in newborn platelets: cause of abnormal response to epinephrine
BR112012031071A2 (pt) 8-proteínas de ligação à il-1
BRPI0312818B8 (pt) uso de uma medida do nível do polipeptídeo sflt-1 em uma amostra de uma paciente e uso de uma medida dos níveis de pelo menos dois dos peptídeos sflt1, vegf livre ou polipeptídio pigf livre em uma amostra de um paciente usando um métrico
BR112018069050A2 (pt) composição aquosa de ligação
BRPI0415448A (pt) método de alvejar populações de célula especìfica empregando-se conjugados de maytansinoid de agente de ligação celular ligados por meio de um ligante não-clivável, os referidos conjugados, e métodos de preparação dos referidos conjugados
BR0210720A (pt) Composto e uso do mesmo
EP1687283A4 (en) FOR THE DETERMINATION OF FK506 PROCEDURE AND COMPOSITION
FI901916A7 (fi) Diagnostinen testipakkaus, alukekoostumus, ja näiden käyttö nukleiinihappojen replikaatioon tai havaitsemiseen
Cutler et al. In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna
Marinov et al. Intra‐and interlaboratory variability of Paroxysmal Nocturnal Hemoglobinuria testing by flow cytometry following the 2012 practical guidelines for high‐sensitivity paroxysmal nocturnal hemoglobinuria testing
Halperin et al. Transient changes in erythrocyte membrane permeability are induced by sublytic amounts of the complement membrane attack complex (C5b-9)
Paulsson et al. Structure and function of basement membrane proteoglycans
KIM et al. The prevalence of obesity and underweight in adolescents in Incheon area and the relationship between serum cholesterol level and obesity
ATE240985T1 (de) Flammfeste polyvinylarenzusammensetzungen
BRPI0409260A (pt) composição contendo polianilina
Larsson et al. On the binding of the bisquaternary ammonium compound paraquat to melanin and cartilage in vivo
BR9814676A (pt) éteres de celulose contendo grupos butenila e seu uso como colóides protetores para polimerização
Madtes Jr et al. Sensitivity of GABA-displaceable [3H] muscimol binding depends upon the composition of the buffering medium
Fabris et al. Platelet serotonin and platelet aggregation in the differential diagnosis of thrombocytosis
BR112018016728A2 (pt) estabilizadores para melhorar a estabilidade de armazenamento de formulações secas de material de construção contendo pó de polímero
Susan et al. Bond strength of self-adhesive resin cements to tooth structure
Holle et al. Focal adhesion mechanotransduction regulates stiffness-directed differentiation

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.